1057PDFINAL RESULTS FROM A CANCER RESEARCH UK FIRST IN MAN PHASE I TRIAL OF IMA950 (A NOVEL MULTI PEPTIDE VACCINE) PLUS GM-CSF IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

Abstract Aim: To determine the safety and immunogenicity of IMA950, a novel multi-peptide glioblastoma (GBM) specific therapeutic vaccine that contains 11 HLA-binding tumour-associated peptides (TUMAPs), identified on human leukocyte antigen (HLA) surface receptors in primary human GBM tissue. Metho...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of oncology 2014-09, Vol.25 (suppl_4), p.iv364-iv365
Hauptverfasser:	Halford, S., Rampling, R., James, A., Peoples, S., Mulholland, P., Al-Salihi, O., Twelves, C., McBain, C., Jefferies, S., Kutscher, S., Hilf, N., McGuigan, L., Peters, J., Roberts, K., Schoor, O., Ritchie, J., Singh-Jasuja, H.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!